Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Epstein

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
Nanomedicine : Nanotechnology, Biology, and Medicine|February 13, 2007
Biocompatible nanofiber scaffolds on metal for controlled release and cell colonizationWenjun Dong, Tierui Zhang, Michelle McDonald, et al.
Journal of Managed Care Pharmacy : JMCP|May 18, 2007
Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturersMichael B Nichol, Tara K Knight, Joshua Epstein, et al.
Blood|October 9, 2014
Curing myeloma at last: defining criteria and providing the evidenceBart Barlogie, Alan Mitchell, Frits van Rhee, et al.
British Journal of Haematology|February 14, 2002
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activityShmuel Yaccoby, Roger N Pearse, Cherie L Johnson, et al.
Blood|October 24, 2002
Antimyeloma efficacy of thalidomide in the SCID-hu modelShmuel Yaccoby, Cherie L Johnson, Susan C Mahaffey, et al.
Cancer Research|March 18, 2004
Cancer and the microenvironment: myeloma-osteoclast interactions as a modelShmuel Yaccoby, Michele J Wezeman, Aminah Henderson, et al.
British Journal of Haematology|December 8, 2009
Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myelomaYa-Wei Qiang, Yu Chen, Nathan Brown, et al.
Annals of Hematology|January 18, 2013
Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional studyHartmut Pollmann, Robert Klamroth, Natascha Vidovic, et al.
BMC Bioinformatics|April 19, 2015
Removing batch effects from purified plasma cell gene expression microarrays with modified ComBatCaleb K Stein, Pingping Qu, Joshua Epstein, et al.
Genes, Chromosomes & Cancer|March 19, 2014
In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genesErming Tian, Jeffrey R Sawyer, Christoph J Heuck, et al.
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Nanomedicine : Nanotechnology, Biology, and Medicine|February 13, 2007
Biocompatible nanofiber scaffolds on metal for controlled release and cell colonizationWenjun Dong, Tierui Zhang, Michelle McDonald, et al.
Journal of Managed Care Pharmacy : JMCP|May 18, 2007
Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturersMichael B Nichol, Tara K Knight, Joshua Epstein, et al.
Blood|October 9, 2014
Curing myeloma at last: defining criteria and providing the evidenceBart Barlogie, Alan Mitchell, Frits van Rhee, et al.
British Journal of Haematology|February 14, 2002
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activityShmuel Yaccoby, Roger N Pearse, Cherie L Johnson, et al.
Blood|October 24, 2002
Antimyeloma efficacy of thalidomide in the SCID-hu modelShmuel Yaccoby, Cherie L Johnson, Susan C Mahaffey, et al.
Cancer Research|March 18, 2004
Cancer and the microenvironment: myeloma-osteoclast interactions as a modelShmuel Yaccoby, Michele J Wezeman, Aminah Henderson, et al.
British Journal of Haematology|December 8, 2009
Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myelomaYa-Wei Qiang, Yu Chen, Nathan Brown, et al.
Annals of Hematology|January 18, 2013
Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional studyHartmut Pollmann, Robert Klamroth, Natascha Vidovic, et al.
BMC Bioinformatics|April 19, 2015
Removing batch effects from purified plasma cell gene expression microarrays with modified ComBatCaleb K Stein, Pingping Qu, Joshua Epstein, et al.
Genes, Chromosomes & Cancer|March 19, 2014
In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genesErming Tian, Jeffrey R Sawyer, Christoph J Heuck, et al.
Pageof 9